Paul Kemp has been involved in commercial regenerative medicine for over 20 years. He has a successful track record in virtually all aspects of the private and public Biotech business in both the USA and UK, from founding biotech companies, raising significant public, private and non-equity based funding in Europe, the USA and Asia to taking a regenerative medicine company public; designing, building and operating GMP facilities in the USA and UK; designing and operating clinical trials including extensive interactions with the MHRA, EMA and FDA; running multi-national, multi-centre Phase I, II and III studies, and finally, launching, marketing and selling cell-based products both in the USA and UK. He is the inventor on several patents related to multiple regenerative medicine products both in development and on the market and publishes and presents widely in the field. He holds a BSc from the University of Wales and a PhD from the University of Leeds. He is Chairman of the Industrial Group of Regener8 and on the editorial board of Regenerative Medicine, the industry journal. He is also Chief Executive and Chief Scientific Officer of Intercytex.